A detailed history of Deep Track Capital, LP transactions in 4 D Molecular Therapeutics, Inc. stock. As of the latest transaction made, Deep Track Capital, LP holds 4,096,452 shares of FDMT stock, worth $23.8 Million. This represents 1.63% of its overall portfolio holdings.

Number of Shares
4,096,452
Previous 4,061,401 0.86%
Holding current value
$23.8 Million
Previous $85.2 Million 48.06%
% of portfolio
1.63%
Previous 2.8%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$10.81 - $27.22 $378,901 - $954,088
35,051 Added 0.86%
4,096,452 $44.3 Million
Q2 2024

Aug 14, 2024

BUY
$20.93 - $30.01 $21.5 Million - $30.8 Million
1,026,948 Added 33.84%
4,061,401 $85.2 Million
Q1 2024

May 15, 2024

BUY
$17.03 - $35.87 $12.8 Million - $26.9 Million
750,081 Added 32.84%
3,034,453 $96.7 Million
Q4 2023

Feb 14, 2024

SELL
$9.76 - $21.25 $4.82 Million - $10.5 Million
-493,735 Reduced 17.77%
2,284,372 $46.3 Million
Q2 2023

Aug 14, 2023

BUY
$15.16 - $23.26 $7.58 Million - $11.6 Million
500,000 Added 21.95%
2,778,107 $50.2 Million
Q1 2023

May 15, 2023

SELL
$15.45 - $23.19 $5.85 Million - $8.78 Million
-378,794 Reduced 14.26%
2,278,107 $39.2 Million
Q4 2022

Feb 14, 2023

SELL
$6.85 - $25.46 $3.7 Million - $13.7 Million
-539,741 Reduced 16.88%
2,656,901 $59 Million
Q3 2022

Nov 14, 2022

BUY
$6.96 - $11.48 $394,228 - $650,250
56,642 Added 1.8%
3,196,642 $25.7 Million
Q2 2022

Aug 12, 2022

BUY
$5.68 - $15.99 $3.93 Million - $11.1 Million
691,800 Added 28.26%
3,140,000 $21.9 Million
Q1 2022

May 16, 2022

BUY
$13.16 - $22.64 $7.21 Million - $12.4 Million
548,200 Added 28.85%
2,448,200 $37 Million
Q4 2021

Feb 14, 2022

BUY
$19.56 - $32.94 $37.2 Million - $62.6 Million
1,900,000 New
1,900,000 $41.7 Million

Others Institutions Holding FDMT

About 4D Molecular Therapeutics, Inc.


  • Ticker FDMT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 32,382,400
  • Market Cap $188M
  • Description
  • 4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical tr...
More about FDMT
Track This Portfolio

Track Deep Track Capital, LP Portfolio

Follow Deep Track Capital, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Deep Track Capital, LP, based on Form 13F filings with the SEC.

News

Stay updated on Deep Track Capital, LP with notifications on news.